<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="Article Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in" exact="Russia" post="and Predicted Susceptibility to INSTIs https://orcid.org/0000-0002-7116-0138KirichenkoAlina1*https://orcid.org/0000-0002-6328-1415LapovokIlya1BaryshevPavel1van de VijverDavid A."/>
 <result pre="A6 integrase INSTI L74I polymorphisms genetic barrier founder effect phylogenetics" exact="Russia" post="1. Introduction It was estimated that more than 1"/>
 <result pre="than 1 million individuals were living with HIV-1 in the" exact="Russian Federation" post="at the end of 2019, which is 0.7% of"/>
 <result pre="INSTI drug approved for the treatment of HIV-infected patients in" exact="Russia" post="in 2008, followed by DTG and EVG in 2014"/>
 <result pre="participants experienced virological failure. Interestingly, these patients were all from" exact="Russia" post="and had an HIV infection with subtype A and"/>
 <result pre="2 treatment experience participants with the L74I mutation from the" exact="Russian Federation" post="with virological failure after therapy containing CAB [16]. The"/>
 <result pre="subtype A sequences [17]; however, according to previous studies in" exact="Russia" post="and the former Soviet Union (FSU) countries, the prevalence"/>
 <result pre="however, according to previous studies in Russia and the former" exact="Soviet Union" post="(FSU) countries, the prevalence of this mutation varied from"/>
 <result pre="which may have important implications for INSTI therapy [13,22,34,35,36,37,38,39,40]. In" exact="Russia" post="and FSU countries, the HIV-1 epidemic is dominated by"/>
 <result pre="viral clade [18,19,20,21]. Therefore, the expanded use of INSTIs in" exact="Russia" post="makes it urgent to analyze the HIV-1 integrase gene."/>
 <result pre="with L74M, including 7 samples from Uzbekistan, one sample from" exact="Russia" post="(Tomsk), and one sample from Kuwait. However, analysis of"/>
 <result pre="distance between these samples showed that only 7 sequences from" exact="Uzbekistan" post="differ by less than 1% (0.2â€&quot;1.0%), which suggests an"/>
 <result pre="epidemiological link between the samples. Notably, two outlier sequences from" exact="Italy" post="(A6.IT.2002.60000. EU861977) and Russia (A6.RU.2000.RU00051. EF545108) with L74L were"/>
 <result pre="samples. Notably, two outlier sequences from Italy (A6.IT.2002.60000. EU861977) and" exact="Russia" post="(A6.RU.2000.RU00051. EF545108) with L74L were placed close to the"/>
 <result pre="at the early stage of the epidemic among injectors in" exact="Russia" post="and subsequently spread as a founder effect in Russia"/>
 <result pre="in Russia and subsequently spread as a founder effect in" exact="Russia" post="and other regions. The phylodynamic analysis revealed that the"/>
 <result pre="the most recent common ancestor (tMRCA) for sub-subtype A6 in" exact="Russia" post="was 1998 (95% HPD: 1989â€&quot;2003). tMRCA is considered the"/>
 <result pre="the genetic features of HIV-1 integrase sub-subtype A6, which dominated" exact="Russia" post="and spread successfully across FSU countries and evolved into"/>
 <result pre="2015. Because the use of INSTIs was introduced recently in" exact="Russia" post="[6], we found a low level of INSTI DR."/>
 <result pre="for the treatment of HIV-infected ARV-naÃ¯ve and ARV-experienced patients in" exact="Russia" post="will be successful. However, not only DRMs can affect"/>
 <result pre="A1 viruses. Taking into account that the A6 virus dominating" exact="Russia" post="may be misclassified as A1, these gene features allow"/>
 <result pre="of virological failures in patients with the L74I mutation from" exact="Russia" post="in the ATLAS and FLAIR studies [15,16]. In vitro"/>
 <result pre="to HIV integrase strand transfer inhibitors among clinical specimens in" exact="the United States," post="2009â€&quot;2012Clin. Infect. Dis.20135842343110.1093/cid/cit69724145878 10.DelelisO.CarayonK.SaÃ¯bA.DeprezE.MouscadetJ.-F.Integrase and integration: Biochemical activities of"/>
 <result pre="HIV integrase strand transfer inhibitors among clinical specimens in the" exact="United States," post="2009â€&quot;2012Clin. Infect. Dis.20135842343110.1093/cid/cit69724145878 10.DelelisO.CarayonK.SaÃ¯bA.DeprezE.MouscadetJ.-F.Integrase and integration: Biochemical activities of"/>
 <result pre="pol gene region coding for HIV-1 integrase in patients from" exact="Russia" post="and UkraineHIV Infect. Immunosuppressive Disord.201247381 21.KazennovaE.V.LapovokI.A.LagaV.Y.VasilyevA.V.BobkovaM.R.Natural polymorphisms of HIV-1"/>
 <result pre="HIV-1 CRF01_AE integrase coding region in ARV-naÃ¯ve individuals in Cambodia," exact="Thailand" post="and Vietnam: An ANRS AC12 working group studyInfect. Genet."/>
 <result pre="54.AcharyaA.TagnyC.T.MbanyaD.FonsahJ.Y.NchindapE.KenmogneL.MaJ.NjamnshiA.KanmogneG.D.Variability in HIV-1 Integrase Gene and 3â€²-Polypurine Tract Sequences in" exact="Cameroon" post="Clinical Isolates, and Implications for Integrase Inhibitors EfficacyInt. J."/>
</results>
